Annovis Bio's Recent Phase II/III Alzheimer's Study Of Buntanetap, Showed Statistically Significant Efficacy And Safety In Both Carriers And Non-Carriers Of Apolipoprotein E4, A Genetic Cause Of AD
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio Inc. (NYSE:ANVS) announced that its Phase II/III study of Buntanetap for Alzheimer's disease showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4. The study demonstrated improvements in cognitive scores and comparable safety across patient groups.
June 11, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annovis Bio's Phase II/III study of Buntanetap for Alzheimer's disease showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4. This positive result could boost investor confidence and potentially increase the stock price.
The positive results from the Phase II/III study of Buntanetap, showing significant efficacy and safety, are likely to boost investor confidence in Annovis Bio. This could lead to a short-term increase in the stock price as the market reacts to the promising data.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100